Skip to content
Screener

BioMarin Pharmaceuticals BMRN PALYNZIQ — Total revenues

Other product segments

VOXZOGO
$252.53M+14.1%
VIMIZIM
$194.37M-9.8%
NAGLAZYME
$135.26M+5.0%
GALAFOLD
$105.75M—
BRINEURA
$51.37M+5.5%
ALDURAZYME
$43.54M-22.9%
POMBILITI + OPFOLDA
$30.26M—
KUVAN
$24.44M-9.6%
ROCTAVIAN
$11.71M+27.3%
Royalty and other revenues
$5.32M-57.2%

Similar metrics at other companies

Sonida Senior Living logo
SNDAResident revenue — Total revenues
$108.43M+36.8%
Asset Entities logo
ASSTOther revenue — Total revenues
$43K+514%
ALN
ALNYRoyalty revenue — Total revenues
$71.67M+79.3%
Hyatt Hotels logo
HContra revenue — Total revenues
-$17M-13.3%
FTAI Aviation Ltd. logo
FTAIMaintenance revenue — Total revenues
$30.6M-38.3%
FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Metabolic Conditions (formerly Enzyme Therapies):
VIMIZIM194,371215,424404,575403,770
NAGLAZYME135,255128,867265,329243,157
PALYNZIQ135,167105,938224,725199,207
GALAFOLD(1)105,748—105,748—
BRINEURA51,37048,69298,47489,054
ALDURAZYME43,53956,43780,281105,414
POMBILITI + OPFOLDA(1)30,258—30,258—

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's PALYNZIQ — total revenues?
BioMarin Pharmaceuticals (BMRN) reported PALYNZIQ — total revenues of $135.17M in Q2 2026.
How has BioMarin Pharmaceuticals's PALYNZIQ — total revenues changed year-over-year?
BioMarin Pharmaceuticals's PALYNZIQ — total revenues increased by 27.6% year-over-year, from $105.94M to $135.17M.
What is the long-term trend for BioMarin Pharmaceuticals's PALYNZIQ — total revenues?
Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's PALYNZIQ — total revenues has grown at a 16.2% compound annual growth rate (CAGR), from $237.47M to $433.31M.
What does PALYNZIQ — total revenues mean?
This metric represents the total gross revenue generated from the sale of a specific therapeutic product within the company's rare disease portfolio. It encompasses all recognized sales, including adjustments for rebates, discounts, and returns, reflecting the overall market adoption and commercial performance of this specific treatment. This figure is a key indicator of the product's lifecycle stage and its contribution to the company's total top-line growth.

Ask your AI about BioMarin Pharmaceuticals's palynziq — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude